Risk Factors for Interstitial Cystitis in the General Population and in Individuals With Depression.
Depression
Inflammation
Interstitial cystitis
Retrospective cohort study
Risk factors
Journal
International neurourology journal
ISSN: 2093-4777
Titre abrégé: Int Neurourol J
Pays: Korea (South)
ID NLM: 101534513
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
27
07
2018
accepted:
01
10
2018
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
5
4
2019
Statut:
ppublish
Résumé
To identify risk factors for interstitial cystitis (IC), a chronic bladder disorder that may have a significant detrimental impact on quality of life, in the general population and in individuals with depression. This was a comparative study using a US claims database. Adults who had records of a visit to the health system in 2010 or later were included. The outcome was the development of IC within 2 years after the index date. The index date for the general population was the first outpatient visit, and for individuals with depression, it was the date of the diagnosis of depression. IC was defined using the concepts of ulcerative and IC. We included all medical conditions present any time prior to the index visit as potential risk factors. The incidence of IC was higher in individuals with depression than in the general population. Of the 3,973,000 subjects from the general population, 2,293 (0.06%) developed IC within 2 years. Of the 249,200 individuals with depression, 320 (0.13%) developed IC. The characteristics of the individuals who developed IC were similar in both populations. Those who developed IC were slightly older, more likely to be women, and had more chronic pain conditions, malaise, and inflammatory disorders than patients without IC. In the general population, subjects who developed IC were more likely to have mood disorders, anxiety, and hypothyroidism. The incidence of IC was higher in individuals with depression. Subjects who developed IC had more chronic pain conditions, depression, malaise, and inflammatory disorders.
Identifiants
pubmed: 30943693
pii: inj.1836182.091
doi: 10.5213/inj.1836182.091
pmc: PMC6449659
doi:
Types de publication
Journal Article
Langues
eng
Pagination
40-45Références
Pharmacoeconomics. 2006;24(1):55-65
pubmed: 16445303
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1093-6
pubmed: 18265925
BMC Psychiatry. 2009 Oct 23;9 Suppl 1:S1
pubmed: 19857242
Int Urogynecol J. 2011 Apr;22(4):395-400
pubmed: 20811877
Chin Med J (Engl). 2010 Oct;123(20):2842-6
pubmed: 21034594
Ann Intern Med. 2010 Nov 2;153(9):600-6
pubmed: 21041580
J Urol. 2011 Aug;186(2):540-4
pubmed: 21683389
J Biomed Inform. 2012 Aug;45(4):689-96
pubmed: 22683994
BJU Int. 2012 Dec;110(11 Pt C):E903-9
pubmed: 23020942
Urology. 2012 Dec;80(6):1227-31
pubmed: 23206765
Int Neurourol J. 2012 Dec;16(4):159-68
pubmed: 23346481
BMC Med. 2013 Sep 12;11:200
pubmed: 24228900
Auton Neurosci. 2014 May;182:89-94
pubmed: 24412640
Int J Urol. 2014 Aug;21(8):805-9
pubmed: 24724573
Int J Urol. 2014 Apr;21 Suppl 1:75-8
pubmed: 24807505
Int J Womens Health. 2015 Jul 23;7:735-44
pubmed: 26229509
Nat Rev Immunol. 2016 Jan;16(1):22-34
pubmed: 26711676
Int J Urol. 2016 Jul;23(7):542-9
pubmed: 27218442
J Clin Psychiatry. 2016 Dec;77(12):1666-1671
pubmed: 27337107
Pain. 2017 Oct;158(10):1979-1991
pubmed: 28692006